StockData
Johnson & Johnson logo

Johnson & Johnson (JNJ) operating KPIs

JNJNYSEPharmaceutical PreparationsFiscal year ends January 3
Financials through Q2 FY2026, quarter ended Jun 28, 2026Last filing: 10-Q on Oct 21, 2026Score 12/3043% above fair value
$273.20−2.00 (-0.73%)

Close on Oct 30, 2026Market cap $658.38BP/E 31.7Yield 1.88%

Johnson & Johnson vELCADE (bortezomib) [reported separately through FY2020Q4] — Worldwide sales ($M) ($M)

Form 10-Q / 10-K Segment Note & Form 8-K EX-99.2 Segment Sales Schedule

QuarterlyAnnual
Latest, FY2020
408
Period ended Jan 3, 2021
Change on a year earlier
-45.7%
751 in FY2019
History
5 years
Since FY2016
Sources
2
Documents cited below

Annual history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedVELCADE (bortezomib) [reported separately through FY2020Q4] — Worldwide sales ($M) ($M)Year on yearSource
FY2020Jan 3, 2021408-45.7%Form 10-K (filed 2021-02-22) ↗
FY2019Dec 29, 2019751-32.7%Form 10-K (filed 2021-02-22) ↗
FY2018Dec 30, 20181,116+0.2%Form 10-K (filed 2021-02-22) ↗
FY2017Dec 31, 20171,114-9.0%Form 10-K (filed 2019-02-20) ↗
FY2016Jan 1, 20171,224–Form 10-K (filed 2019-02-20) ↗

Breakdown

What makes up velcade (bortezomib) [reported separately through fy2020q4] — worldwide sales ($m)

Cite this data

StockData. (2026). Johnson & Johnson VELCADE (bortezomib) [reported separately through FY2020Q4] — Worldwide sales ($M) ($M), annual FY2016–FY2020 [Data set]. Compiled from Johnson & Johnson SEC filings and investor materials. https://stockdatahq.com/stocks/jnj/kpis/drug_velcade

See every metric in the Johnson & Johnson KPI table. Data updated Oct 25, 2026.